With Johnson & Johnson battling talc and opioid lawsuits and now a Risperdal verdict, has its storied stalwart reputation reached a tipping point? That’s what reputation management agency Alva wanted to find out, and it sifted through four years of perspectives
read moreEli Lilly has scored its next migraine drug approval. While its 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur. More: Lilly scores FDA nod for new migraine drug Reyvow Source: fierce
read moreDrug-cost watchdog Institute for Clinical and Economic Review is out with its new draft assessment of JAK inhibitors to treat rheumatoid arthritis, which incorporates different assumptions about how physicians treat the disease and the time horizon that should be considered
read moreJohnson & Johnson is facing not one but two major litigation roundups over sales of its opioids and talcum powder products, leaving its share price “historically cheap.” But even as a pair of massive settlements loom, one analyst says he sees
read moreAlready behind in the PARP inhibitor race, Clovis Oncology’s Rubraca has at least won a reserved backing from England’s drug cost watchdog that helps level the playground in the U.K. region. Now, the late-comer will have to face two Big
read moreSo far in his tenure, Sanofi CEO Paul Hudson has been busy learning about the company’s operations. As he works to formulate a new strategy for the company, he visited the U.K. for the opening ceremony of a £37 million
read more© 1994 - 2026 B.M. Pharmaceuticals